Busy IPO week winds down as two more biotechs — and one look­ing to im­prove clin­i­cal tri­als — file for pub­lic de­buts

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Two more biotech com­pa­nies — and one that’s com­mit­ted to sup­port­ing clin­i­cal re­search — filed for IPOs just be­fore the long week­end.

No­bel lau­re­ate Jen­nifer Doud­na’s Cari­bou Bio­sciences is pen­cil­ing in a $100 mil­lion raise to sup­port its off-the-shelf CAR-T ther­a­pies, one of which is mak­ing its way through a Phase I study in B-cell non-Hodgkin lym­phoma. Al­so look­ing for a $100 mil­lion raise is WCG Clin­i­cal Ser­vices, which es­tab­lished it­self as an al­ly to bio­phar­ma com­pa­nies and CROs back in 2012. The com­pa­ny of­fers plan­ning, pa­tient en­gage­ment, and eth­i­cal re­view ser­vices, and says it was be­hind more than 723 Covid-19 tri­als. Mean­while, transpa­cif­ic biotech Brii Bio­sciences is look­ing for its own tick­er on the Hong Kong Stock Ex­change, and says it’ll use the funds across its broad in­fec­tious dis­ease and CNS pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER